AKERO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.2 USD | +6.52% |
|
-3.25% | -0.64% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 633.9 | 895.8 | 737.9 | 2,563 | 1,301 | 1,604 | - | - |
| Enterprise Value (EV) 1 | 633.9 | 627.4 | 549.6 | 2,221 | 775.8 | 879.1 | 1,129 | 1,157 |
| P/E ratio | -7.65 x | -10.2 x | -7.32 x | -19.1 x | -8.08 x | -6.25 x | -5.34 x | -5.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 57.1 x |
| EV / Revenue | - | - | - | - | - | - | - | 41.2 x |
| EV / EBITDA | -13.9 x | -8.47 x | -5.45 x | -19.3 x | -4.49 x | -3.42 x | -3.91 x | -3.84 x |
| EV / FCF | -17.8 x | -8.84 x | -6.9 x | -24 x | -5.34 x | -4.9 x | -5.53 x | -5.1 x |
| FCF Yield | -5.62% | -11.3% | -14.5% | -4.17% | -18.7% | -20.4% | -18.1% | -19.6% |
| Price to Book | 2.6 x | 3.46 x | 4.36 x | 6.54 x | 2.29 x | 2.28 x | 3.72 x | 4.47 x |
| Nbr of stocks (in thousands) | 28,559 | 34,722 | 34,888 | 46,763 | 55,710 | 69,151 | - | - |
| Reference price 2 | 22.20 | 25.80 | 21.15 | 54.80 | 23.35 | 23.20 | 23.20 | 23.20 |
| Announcement Date | 16/03/20 | 16/03/21 | 25/02/22 | 17/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 28.07 |
| EBITDA 1 | -45.65 | -74.12 | -100.8 | -115.1 | -172.8 | -256.8 | -288.4 | -301.7 |
| EBIT 1 | -45.65 | -80.15 | -100.9 | -115.2 | -172.9 | -254.3 | -293.6 | -299.2 |
| Operating Margin | - | - | - | - | - | - | - | -1,065.97% |
| Earnings before Tax (EBT) 1 | -43.76 | -79.21 | -100.8 | -112 | -151.8 | -243.3 | -283.5 | -280 |
| Net income 1 | -43.76 | -79.21 | -100.8 | -112 | -151.8 | -239.5 | -283.7 | -306.5 |
| Net margin | - | - | - | - | - | - | - | -1,091.77% |
| EPS 2 | -2.900 | -2.520 | -2.890 | -2.870 | -2.890 | -3.712 | -4.342 | -4.002 |
| Free Cash Flow 1 | -35.63 | -70.95 | -79.68 | -92.52 | -145.4 | -179.5 | -204 | -226.7 |
| FCF margin | - | - | - | - | - | - | - | -807.43% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 16/03/20 | 16/03/21 | 25/02/22 | 17/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -32.43 | -26.04 | -27.58 | -36.08 | -25.41 | -28.74 | -35.62 | -46.61 | -61.87 | -59.95 | -65 | -71 | -77 | - | - |
| EBIT 1 | -32.44 | -26.05 | -27.59 | -36.09 | -25.42 | -28.75 | -35.63 | -46.62 | -61.87 | -59.95 | -61.35 | -63.9 | -71.64 | -67.6 | -69.95 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -32.42 | -26.03 | -27.4 | -35.54 | -23.06 | -25.83 | -31.08 | -39.66 | -55.19 | -53.34 | -57.25 | -60.75 | -72.48 | - | - |
| Net income 1 | -32.42 | -26.03 | -27.4 | -35.54 | -23.06 | -25.83 | -31.08 | -39.66 | -55.19 | -53.34 | -56.15 | -59.02 | -67.52 | -68.85 | -71.21 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.9300 | -0.7400 | -0.7700 | -0.9200 | -0.4900 | -0.5500 | -0.6000 | -0.7100 | -0.9900 | -0.9000 | -0.8478 | -0.8915 | -1.012 | -1.207 | -1.060 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 25/02/22 | 06/05/22 | 05/08/22 | 04/11/22 | 17/03/23 | 15/05/23 | 11/08/23 | 13/11/23 | 29/02/24 | 10/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 268 | 188 | 342 | 525 | 725 | 476 | 447 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -35.6 | -71 | -79.7 | -92.5 | -145 | -180 | -204 | -227 |
| ROE (net income / shareholders' equity) | -111% | -40.9% | -47.1% | -45.2% | -35.2% | -40.7% | -64% | -74.6% |
| ROA (Net income/ Total Assets) | -40.7% | -38.5% | -43% | -40.6% | -32.4% | -38.4% | -40.9% | -44.5% |
| Assets 1 | 107.6 | 205.7 | 234.4 | 276.1 | 468.4 | 623.7 | 694.4 | 689.2 |
| Book Value Per Share 2 | 8.540 | 7.450 | 4.860 | 8.380 | 10.20 | 10.20 | 6.240 | 5.190 |
| Cash Flow per Share 2 | - | - | -2.290 | - | - | -2.670 | -3.350 | - |
| Capex 1 | - | - | - | - | - | 3.86 | 5.71 | 7.14 |
| Capex / Sales | - | - | - | - | - | - | - | 25.44% |
| Announcement Date | 16/03/20 | 16/03/21 | 25/02/22 | 17/03/23 | 29/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.2
USD
Average target price
44.56
USD
Spread / Average Target
+92.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.64% | 1.6B | |
| +15.19% | 121B | |
| +19.91% | 114B | |
| -19.80% | 20.43B | |
| -16.19% | 16.55B | |
| -13.45% | 16.45B | |
| -44.35% | 15.59B | |
| +66.67% | 15.19B | |
| +2.13% | 13.54B | |
| +119.39% | 10.96B |
- Stock Market
- Equities
- AKRO Stock
- Financials Akero Therapeutics, Inc.
